P. Corn

Bruce Montgomery, Javed Siddiqui, Walter M Stadler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer

Parantu K. Shah, B. Broom, Wenjun Chang, 2014, Science Signaling.

CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment

P. Troncoso, C. Logothetis, M. Frazier, 2016, Nature Communications.

Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

J. Herman, S. Baylin, J. Costello, 1999, Cancer research.

Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

A. Chinnaiyan, E. Vazquez, N. Palanisamy, 2014, Science Translational Medicine.

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

B. Broom, G. Peng, T. Thompson, 2021, Clinical Cancer Research.

Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer

J. Hicks, N. Navin, C. Logothetis, 2020, Clinical Cancer Research.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Oliver Sartor, Susan Halabi, Lawrence H Schwartz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

N. Navin, P. Troncoso, E. Heath, 2019, The Lancet. Oncology.

Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression

P. Troncoso, C. Logothetis, T. Thompson, 2012 .

Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

P. Tamboli, E. Jonasch, T. Choueiri, 2010, Cancer.

Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.

J. Herman, S. Baylin, E. Gabrielson, 1998, Cancer research.

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development

P. Corn, 2012, Cancer management and research.

Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer

P. Corn, A. Zurita, P. Kuhn, 2021, Molecular Cancer Research.

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

K. Hess, F. Meric-Bernstam, R. Kurzrock, 2015, Clinical genitourinary cancer.

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

R. Millikan, B. Czerniak, C. Dinney, 2016, European urology.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.

J. Herman, S. Baylin, M. Esteller, 1999, Cancer research.

Role of the ubiquitin proteasome system in renal cell carcinoma

P. Corn, Paul G Corn, 2007, BMC Biochemistry.

Inhibition of Mxi1 suppresses HIF-2α-dependent renal cancer tumorigenesis

Bin Tean Teh, Christopher J. Logothetis, Eric Jonasch, 2008 .

Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy

K. Hess, C. Logothetis, P. Corn, 2017, Cancer Chemotherapy and Pharmacology.

The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC).

N. Navin, B. Broom, P. Troncoso, 2017 .

A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC).

E. Jonasch, E. Heath, C. Logothetis, 2015 .

Src signaling pathways in prostate cancer

P. Corn, G. Gallick, J. Araujo, 2014, Cancer and Metastasis Reviews.

Novel therapies for metastatic castrate-resistant prostate cancer.

C. Logothetis, P. Corn, G. Gallick, 2011, Journal of the National Cancer Institute.

A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC).

C. Logothetis, P. Corn, S. Tu, 2018 .

Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

T. Thompson, P. Corn, 2010, Cancer management and research.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer

B. Czerniak, C. Logothetis, P. Corn, 2015, Clinical Cancer Research.

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

C. Logothetis, P. Corn, G. Gallick, 2011, Expert opinion on investigational drugs.

A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.

P. Troncoso, C. Logothetis, P. Corn, 2020, Clinical genitourinary cancer.

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

E. Jonasch, M. Harrison, Rajan T. Gupta, 2021, Cancer medicine.

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

P. Corn, Sue-Hwa Lin, A. Zurita, 2012, Future medicinal chemistry.

The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan

P. Corn, B. Andersson, B. Valdez, 2014, Leukemia & lymphoma.

MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines

P. Corn, C. C. Tsao, 2010, Cancer biology & therapy.

Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.

A. Chinnaiyan, B. Broom, P. Troncoso, 2021, European urology oncology.

Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment

P. Troncoso, C. Logothetis, P. Corn, 2021, Clinical Cancer Research.

Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome

J. Herman, S. Baylin, L. Aaltonen, 2000, Oncogene.

Methylation marks the path for biomarker development in breast cancer research

P. Corn, 2009, Cancer biology & therapy.

Fibroblast growth factors signaling in bone metastasis

E. Vazquez, C. Logothetis, P. Corn, 2020, Endocrine-related cancer.

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer

C. Logothetis, P. Corn, Sue-Hwa Lin, 2020, Cancers.

Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.

A. Gazdar, A. Virmani, W. El-Deiry, 2003, Carcinogenesis.

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

David C. Smith, E. Basch, H. Scher, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.

R. Millikan, P. Corn, A. Siefker-Radtke, 2015, Clinical Genitourinary Cancer.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity

J. Roth, S. Swisher, C. Logothetis, 2009, Cancer biology & therapy.

Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma

P. Sharma, W. Arap, P. Corn, 2012 .

Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.

C. Logothetis, B. Liu, P. Corn, 2015, Cancer research.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

T. Bathala, E. Jonasch, P. Corn, 2014, The Journal of urology.

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.

R. Millikan, P. Tamboli, E. Jonasch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein

J. Herman, W. El-Deiry, E. McDonald, 2003, Nature Genetics.

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

M. Konopleva, M. Andreeff, I. Samudio, 2008, Leukemia.

Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis.

Christopher Logothetis, Eric Jonasch, B. Teh, 2008, Cancer biology & therapy.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.

R. Millikan, E. Jonasch, P. Corn, 2013, European journal of cancer.

KDM4A promotes NEPC progression through regulation of MYC expression

Min Gyu Lee, B. Foster, P. Troncoso, 2022, bioRxiv.

Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)--A University of Chicago phase II consortium tria

David C. Smith, A. Chinnaiyan, K. Cooney, 2016 .

Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa).

Michael P. Van Alstine, P. Sharma, P. Troncoso, 2017 .

Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma

E. Jonasch, Jianjun Gao, S. Matin, 2021, BJUI compass.

Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer epigenome

P. Corn, 2008 .

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012 .

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer

S. Giordano, P. Corn, M. Wehner, 2021, JAMA network open.

Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.

M. Michaelson, P. Corn, D. George, 2012 .

Clinical Investigation : Genitourinary Cancer PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

D. Kuban, S. McGuire, Andrew K. Lee, 2022 .

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

P. Tamboli, E. Jonasch, C. Wood, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases

P. Tamboli, E. Jonasch, C. Wood, 2016, BJU international.

Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma.

P. Tamboli, E. Jonasch, C. Wood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters

P. Troncoso, C. Logothetis, P. Corn, 2016, Clinical Cancer Research.

Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era.

P. Tamboli, E. Jonasch, C. Wood, 2014 .

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.

S. McGuire, T. Bathala, A. Reuben, 2023, JAMA oncology.

Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND.

T. Bathala, D. Gomez, P. Corn, 2022, International journal of radiation oncology, biology, physics.

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).

David C. Smith, H. Scher, J. Bono, 2012 .

Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules

E. Jonasch, P. Corn, Xuemei Wang, 2013 .

CpG Island Methylation ′ Associated with 5 Lymphoblastic Leukemia and Burkitt ' s Lymphoma Is Gene in Acute p 73 Transcriptional Silencing of the Updated Version

J. Herman, S. Baylin, M. Esteller, 1999 .

Using methylation analysis to assess tumor heterogeneity in familial breast cancer

P. Corn, 2011, Cancer biology & therapy.

Restoration of a Phosphaturic Response to Parathyroid Hormone in the Immature Rat

P. Corn, A. Haramati, S. Mulroney, 1989, Pediatric Research.

Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients.

K. Do, E. Jonasch, P. Corn, 2013 .

Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.

P. Tamboli, E. Jonasch, C. Wood, 2014 .

Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.

Xiaohong Yan, E. Jonasch, Jianjun Gao, 2021 .

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

C. Drake, P. Sharma, P. Troncoso, 2023, Journal for ImmunoTherapy of Cancer.

Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data.

David C. Smith, A. Chinnaiyan, K. Cooney, 2017 .

Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

T. Thompson, P. Corn, Timothy C. Thompson, 2010 .

A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial).

P. Corn, A. Zurita, Xuemei Wang, 2018 .

Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma.

P. Tamboli, E. Jonasch, T. Choueiri, 2010 .

Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC).

P. Troncoso, E. Heath, C. Logothetis, 2016 .

Kidney , Brain , and Other Human Cancers Gene Suggests a Suppressor Role in Metalloproteinase-3 Methylation-associated Silencing of the Tissue Inhibitor of Updated Version

J. Herman, S. Baylin, J. Costello, 1999 .

Genes involved in Haemophilus influenzae type b capsule expression are frequently amplified.

P. Corn, S. Hoiseth, A. Takala, 1993, The Journal of infectious diseases.

Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN).

E. Jonasch, C. Wood, P. Corn, 2009, Journal of Clinical Oncology.

Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC).

E. Jonasch, P. Corn, M. Campbell, 2015 .

Novel therapies for metastatic castrate-resistant prostate cancer.

C. Logothetis, P. Corn, G. Gallick, 2011, Journal of the National Cancer Institute.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.

C. Logothetis, B. Liu, P. Corn, 2015, Cancer Research.

Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters

P. Troncoso, C. Logothetis, P. Corn, 2016, Clinical Cancer Research.

Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.

M. Harrison, K. Hoffman, A. Armstrong, 2020, International journal of radiation oncology, biology, physics.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Reactivation of p53 function with a demethylating agent: Awakening a sleeping giant

P. Corn, 2006, Cancer biology & therapy.

Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.

R. Murthy, D. Ganeshan, A. Tsimberidou, 2016, Clinical genitourinary cancer.

Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderClinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules

T. Bathala, E. Jonasch, P. Corn, 2014 .

Randomized phase 2 study of bone‐targeted therapy containing strontium‐89 in advanced castrate‐sensitive prostate cancer

C. Logothetis, P. Corn, L. Pagliaro, 2015, Cancer.

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma

P. Tamboli, E. Jonasch, C. Ng, 2009, Cancer.

Metastases-Targeting Radiotherapy and ADT-Reply.

P. Corn, Alexander D. Sherry, Chad Tang, 2023, JAMA oncology.

A randomized phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial).

P. Corn, A. Zurita, Xuemei Wang, 2018 .